Skip to content

Study · Not a test of the peptide alone · 2021

3 results

Is oxytocin receptor antagonist administration around embryo transfer associated with IVF treatment success? A systematic review and meta-analysis.

Neumann K, Griesinger G

Reproductive biomedicine online28 Aug 2021Cited by 5 (Europe PMC)

PMID34686417 (opens in a new tab)DOI10.1016/j.rbmo.2021.08.020 (opens in a new tab)PepBankPUB-34686417
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 01HumanNot a test of Oxytocin aloneSystematic reviewEfficacy outcome

    In women having IVF, pooled oxytocin receptor antagonists (atosiban, barusiban, nolasiban) around embryo transfer gave a higher clinical pregnancy rate than placebo or nil.

    In plain wordsIn women having IVF, drugs that block the oxytocin receptor, given around embryo transfer, were linked to more clinical pregnancies than placebo or nothing.

    Peptide
    Oxytocin
    Outcome
    IncreaseClinical pregnancy rate
    Study

    n = 3,611

    Comparator
    Placebo or nil
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Relative risk
    1.31 RR
    clinical pregnancy

    Source sentences

    Summary
    Clinical pregnancy rate was significantly higher in women receiving an OTR-a around embryo transfer (relative risk [RR] 1.31, 95% confidence interval [CI] 1.13-1.51, P = 0.0002, I2 = 61%, n = 11 studies, n = 3611)
    2 context sentences
    Summary · context
    Multiple databases were searched for randomized controlled trials (RCT) comparing the outcome of IVF treatment with administration of an OTR-a before, during or after embryo transfer versus administration of placebo/nil.
    Summary · context
    The active compound was intravenous atosiban (n = 7), subcutaneous barusiban (n = 1) and oral nolasiban (n = 3).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 02HumanNot a test of Oxytocin aloneSystematic reviewEfficacy outcome

    In women having IVF, pooled oxytocin receptor antagonists around embryo transfer did not significantly change the live birth rate versus placebo or nil.

    In plain wordsIn women having IVF, drugs that block the oxytocin receptor did not significantly change live birth rates compared with placebo or nothing.

    Peptide
    Oxytocin
    Outcome
    No significant changeLive birth rate
    Study

    n = 2,765

    Comparator
    Placebo or nil
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Relative risk
    1.09 RR
    live birth

    Source sentences

    Summary
    live birth rate was not statistically significantly affected (RR 1.09, 95% CI 0.98-1.20, P = 0.11, I2 = 25%, n = 5 studies, n = 2765).
    2 context sentences
    Summary · context
    Multiple databases were searched for randomized controlled trials (RCT) comparing the outcome of IVF treatment with administration of an OTR-a before, during or after embryo transfer versus administration of placebo/nil.
    Summary · context
    The active compound was intravenous atosiban (n = 7), subcutaneous barusiban (n = 1) and oral nolasiban (n = 3).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  3. 03HumanNot a test of Oxytocin aloneSystematic reviewEfficacy outcome

    In a sensitivity analysis of low risk of bias trials, pooled oxytocin receptor antagonists gave a higher clinical pregnancy chance than placebo or nil.

    In plain wordsIn the most reliable trials, drugs that block the oxytocin receptor were linked to a higher chance of clinical pregnancy than placebo or nothing.

    Peptide
    Oxytocin
    Outcome
    IncreaseClinical pregnancy rate in low risk of bias studies
    Study

    n = 2,765

    Comparator
    Placebo or nil
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Relative risk
    1.11 RR
    low risk of bias studies

    Source sentences

    Summary
    A sensitivity analysis on low risk of bias studies likewise indicates a higher clinical pregnancy chance (RR 1.11, 95% CI 1.01-1.22, P = 0.03, I2 = 5%, n = 5 RCT, n = 2765).
    2 context sentences
    Summary · context
    Multiple databases were searched for randomized controlled trials (RCT) comparing the outcome of IVF treatment with administration of an OTR-a before, during or after embryo transfer versus administration of placebo/nil.
    Summary · context
    The active compound was intravenous atosiban (n = 7), subcutaneous barusiban (n = 1) and oral nolasiban (n = 3).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.